T Cell Receptors Targeting BRAF V600E Mutation for Cancer Immunotherapy
Summary:
The NCI seeks parties interested in research co-development and/or licensing of these HLA-A*0301 restricted TCRs that target the BRAF V600E mutation.
Cell Lines that Constitutively Express High-Frequency KRAS and P53 Mutations and Human Leukocyte Antigens (HLAs)
Summary:
The NCI seeks parties interested in licensing this library of cell lines stably expressing tumor-specific antigens and HLAs.
Neoantigen T Cell Therapy with Neoantigen Vaccination as a Combination Immunotherapy Against Cancer
Summary:
The NCI seeks parties interested in research co-development and/or licensing of this combination immunotherapy approach of neoantigen-specific T cells administered alongside a neoantigen-targeting vaccine to enhance ACT and treat cancer.
PIM-Targeted PROTACs
Description of Technology:
Proviral Integration for the Moloney murine leukemia virus (PIM) kinases are overexpressed in many solid cancers – including prostate, breast, colon, endometrial, gastric and pancreatic. High of PIM1 expression is predictive of poor survival in multiple cancer types. While several selective pan-PIM inhibitors were developed and tested in clinical trials, all ultimately increased PIM1-3 protein levels and developed intrinsic resistance.
Anti-Glypican 2 Chimeric Antigen Receptor (CAR) Containing CD28 Hinge And Transmembrane Domains For Treating Neuroblastoma
Description of Technology:
Neuroblastomas are the most common extracranial solid tumors in pediatric patients, with 700-800 new cases annually in the United States. Metastatic neuroblastomas have a five-year survival rate of 50% and account for 15% of all pediatric cancer deaths. As such, more effective treatments against high-risk neuroblastomas are urgently needed.
Chimeric Antigen Receptors (CAR)-T Cells that Target the Non-Shed Portion of Mesothelin as a Therapeutic Agent
Description of Technology:
Mesothelin (MSLN) is an excellent target for antibody-based therapies of cancer because of its high expression in many malignancies but lack of expression on essential normal tissues. Unfortunately, a large fragment of MSLN is shed from cancer cells, causing the currently available anti-MSLN antibodies (and immunoconjugates thereof) which bind to the shed portion of MSLN to quickly lose their therapeutic effectiveness over time.
Mice, Organs, and Mouse Alleles Carrying Germline and Conditional Deletions of the Zbtb7b Gene
Summary:
The NCI seeks parties interested in licensing this mouse model, including the mice, organs, tissues, and other derivatives from mice carrying deletions of the Zbtb7b gene.
T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy
Summary:
The NCI seeks parties interested in research co-development and/or licensing this library of TCRs targeting CDKN2A mutations.
High Efficacy Vaccine and Microbicide Combination For Use Against HIV
Summary:
NCI is seeking research co-development partners and/or licensees to evaluate, further develop or commercialize this high efficacy vaccine and microbicide combination for use against HIV.
Use of Repurposed Compounds for the Treatment of Alzheimer’s Disease
Summary:
The NIA seeks co-development partners and/or licensees for the further pre-clinical and clinical development of TTI-101, hydroxychloroquine, and Dasatinib to treat Alzheimer’s disease.